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      INTRODUCTION 
Methotrexate is one of the drugs of choice for 
systemic treatment of moderate to severe forms of 
multiple disorders. Methotrexate is a highly effective 
drug that has been used successfully for more than 
50 years to treat skin diseases.1 At present, 
methotrexate is also used for the treatment of other 
dermatological diseases, such as vasculitis, bullous 
dermatosis, and lymphoproliferative diseases.2 
Methotrexate has proven to be a highly effective 
drug, but half of patients experience ADR during 
treatment. The pathogenesis of most ADR of 
methotrexate is based on its cytotoxic effect on 
rapidly dividing body cells, primarily the cells of the 
bone marrow, gastrointestinal tract, and 
hepatocytes. Methotrexate toxicity effects all the 
major organs of the body. 
 
Gastrointestinal disorders are the most common 
ADR of methotrexate: 18.2% of patients report 
nausea and vomiting; 11.1% have ulcers of the oral 
mucosa and other mucositis; 7.5% have abdominal 
pain; and 6.6% of patients note intestinal functional 
disturbances.3 The primary mechanism of ADR with 
methotrexate therapy is inhibition of folate 
metabolism in tissues with high cell proliferation, 
with a high need for purines, thymidine, and 
methionine. Since gastrointestinal epithelium is 
characterized by a rapid rate of cell population 
turnover, folate deficiency is the major mechanism  
 
 
in the development of this ADR group.4 The 
incidence of gastrointestinal ADR may be influenced 
by the patient’s genetic characteristics, namely the 
presence of polymorphisms in the genes encoding 
the methotrexate transporter proteins. 
  
Hepatotoxicity of methotrexate is one of the most 
significant ADR of the drug.5 The hepatotoxic effect 
of methotrexate is mainly manifested by two ADR 
groups: elevated liver enzymes and development of 
structural changes in the liver.6 Liver enzyme 
elevations occur in 10% of all patients taking 
methotrexate on the average.  
 
Liver fibrosis usually develops with a long-term use 
of methotrexate: such structural changes in the liver 
occur in 25% of patients taking methotrexate for 
more than 5 years.7 While testing liver biopsy 
specimens from patients with rheumatoid arthritis 
treated with methotrexate, accumulation of 
polyglutamate forms of methotrexate and folate 
deficiency was found in cells, which may indicate 
that the hepatotoxicity of methotrexate is associated 
with folate depletion due to the action of 
polyglutamate forms of the drug.8 Polyamine 
synthesis, accumulation of adenosine and 
deoxyadenosine, impaired metabolism of 
homocysteine and purines are also thought to play a 
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methotrexate. According to the results of studies in 
mouse models, the cause of methotrexate-induced 
liver fibrosis is the stimulation of collagen synthesis 
by the accumulation of adenosine: adenosine binds 
adenosine A2 receptors on the hepatic fat-storing 
stellate cells, which are potentially fibrogenic and 
stimulate collagen production.9 Methotrexate 
triggers the lipid peroxidation process, which leads 
to the synthesis of reactive oxygen species and 
damage to liver cells. Possible risk factors for these 
ADR should be considered when predicting the risk 
of methotrexate-induced hepatotoxicity. 
 
Other risk factors for increased hepatotoxicity of 
methotrexate include persistent elevated 
aminotransferases, alcohol use, chronic liver disease, 
history of hepatotoxic drug use or exposure to 
hepatotoxic substances, hereditary predisposition to 
genetically determined liver diseases, alpha-1 
antitrypsin deficiency, and hemochromatosis.6 To 
predict the hepatotoxicity of methotrexate, a 
complete blood count, liver enzyme testing, 
serologic studies to identify hepatitis B and C 
biomarkers, and ruling out other risk factors for 
increased hepatotoxicity, including genetic ones, are 
required before starting therapy. Since the drug is 
excreted by kidneys and impairment of their 
function may increase the risk of hepatotoxicity, 
creatinine and urea levels should be assessed. 
Regular monitoring of aminotransferases as an early 
and reliable marker of liver injury is now considered 
sufficient in the first stages of therapy. Additional 
specific tests to assess liver status are recommended 
in case of risk factors for hepatotoxicity or abnormal 
liver chemistry.  
 
Some patients develop hematologic abnormalities, 
such as myelosuppression manifested by macrocytic 
anemia, leukopenia, lymphopenia, 
thrombocytopenia, hypogammaglobulinemia, and 
pancytopenia. The mechanism of methotrexate-
induced thrombocytopenia is based on the release of 
free oxygen radicals that activate terminal protein 
kinases, which are involved in the initiation of 
platelet apoptosis.10 
 
The risk factors for hematological toxicity include 
the elderly, persons with renal insufficiency, 
hypoalbuminemia, those non-complying with 
dosing regimen of the drug or folic acid, and alcohol 
users. Cases of pancytopenia and thrombocytopenia 
have been described in patients with risk factors 
with low-dose methotrexate. Patients without risk 
factors are advised to monitor blood parameters 
once a week during the first month of methotrexate 
use and every two weeks during the second and third 
months. After the fourth month of therapy, in the 
absence of ADR, the frequency of blood tests can be 
reduced to every 2–3 months. It should be 
considered that 4 to 6 weeks after increasing the 
dose of methotrexate, the risk of hematologic ADR 
increases, and the patient’s state should be closely 
monitored during this period. Since impaired renal 
function is one of the most serious predisposing 
factors for ADR, it is advised to measure the 
glomerular filtration rate in elderly patients and in 
those with reduced body weight, even if the blood 
creatinine and urea nitrogen values are normal. If a 
patient has impaired renal function, each 
subsequent methotrexate intake and dose increase 
should be preceded by test results that do not reveal 
any negative changes. 
 
Patients taking methotrexate have a higher risk of 
interstitial pneumonia, pneumocystis pneumonia, 
and pulmonary fibrosis.6 The phenomena of 
pulmonary toxicity have been observed in patients 
treated with both low and high doses of the drug, 
suggesting that the mechanism of toxicity is not 
conditioned by the methotrexate influence on folate 
metabolism only.11 The alleged and investigated 
mechanisms of the pulmonary toxicity of 
methotrexate are hypersensitivity reactions, direct 
cytotoxic effect of methotrexate on lung tissue, 
activation of mitogen-activated protein kinases, 
immunosuppression, and impaired cytokine 
expression, causing an inflammatory response in 
lung tissues and destruction of lung tissue.12 
Bronchoalveolar lavage and histological 
examination of the lung tissue confirm that the 
pathogenesis of lung injury is based on the 
hypersensitivity reaction.13 Damage to the 
epithelium and manifestations of fibrosis suggest a 
direct cytotoxic mechanism of methotrexate effect.14 
 
The toxic effect of methotrexate on renal function is 
a common ADR at high doses of the drug, but in rare 
cases methotrexate can cause kidney damage 
leading to kidney failure, even at low doses. Various 
mechanisms of low-dose methotrexate 
nephrotoxicity are assumed. Methotrexate has been 
established to cause renal tubular cell edema and 
necrosis, leading to irreversible damage to kidney 
tissue.15 The drug is excreted primarily by the 
kidneys and being relatively insoluble in the acidic 
medium of urine, may have a direct toxic effect on 
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the renal tubular epithelium or precipitate in the 
renal tubular lumen, causing intratubular 
obstruction. These processes result in a decreased 
glomerular filtration rate. Methotrexate causes 
damage to the cells of the renal glomeruli and renal 
tubules by increasing the oxidative stress the role of 
which has been identified in the pathogenesis of 
chronic kidney disease. The mechanism suggested is 
an increase in the markers of oxidative stress, 4-
hydroxynonenal and malonic aldehyde, with long-
term use of low doses of methotrexate [16]. Another 
alleged mechanism of methotrexate-induced 
nephrotoxicity is decreased blood flow in the renal 
tissues and consequently impaired renal excretion of 
water and salts by the kidneys due to the increasing 
adenosine concentrations in the plasma and 
intercellular fluid and subsequent activation of 
adenosine receptors.17 
 
Methotrexate affects the body’s immune response 
and increases the risk of opportunistic infections. 
Cases of pneumocystis pneumonia, atypical 
actinomycosis, aspergillosis, cryptococcosis, 
meningitis and herpes virus infections, reactivation 
of tuberculosis, exacerbations of chronic hepatitis 
have been described with methotrexate treatment. 
Weekly low-dose methotrexate has been established 
to affect T cell activity18, however, it is suggested that 
an increased risk of infectious diseases may be 
caused by imbalance in the immune system due to 
chronic inflammation resulting from the underlying 
disease or the presence of concomitant disorders 
and comorbidities. 
 
Methotrexate is prohibited in pregnant women due 
to the teratogenicity of the drug. Fetal 
malformations have been observed with 
methotrexate at all gestational ages, but the most 
pronounced teratogenic effect of methotrexate is 
observed during the first 6–8 weeks of pregnancy.19 
Methotrexate is also prohibited in lactating women 
because it is found in breast milk and can cause ADR 
in the baby. Oligospermia, a negative effect of 
methotrexate on spermatogenesis, has also been 
described in the literature.20  
 
Methotrexate is a risk factor for the development of 
squamous cell carcinoma of the skin.21 It has been 
found that long-term therapy with methotrexate is 
associated with the development of Epstein-Barr 
virus-associated lymphoproliferative diseases, which 
spontaneously regress after discontinuation of  
methotrexate.22 In addition, a study of the rate of 
malignancy risk increases has found that patients 
with rheumatoid arthritis treated with methotrexate 
were 50% more likely to have cancer compared to 
the general population, with five-fold increased risk 
of non-Hodgkin lymphomas and three-fold 
increased risk of melanoma and lung cancer. 
 
ADR of mucositis, ulceration of psoriatic lesions, 
hyperpigmentation, alopecia, toxic epidermal 
necrolysis, nodulosis, and anaphylaxis have been 
described in patients taking methotrexate.23 One of 
the skin ADR of the drug is methotrexate-induced 
nodulosis. It is assumed that the mechanism of 
formation of these giant cells is based on the 
methotrexate effect on the increase in adenosine 
synthesis and its interaction with adenosine A1 
receptors.24 Methotrexate-induced alopecia is 
thought to be caused by folate deficiency; it rarely 
occurs with low-dose methotrexate and resolves on 
its own several months after therapy 
discontinuation.  
 
At the start of methotrexate therapy, some patients 
experience headaches, dizziness, weakness and 
emotional liability. One of the alleged mechanisms 
of methotrexate-induced neurotoxicity is the effect 
of increased release of adenosine and its 
accumulation in the central nervous system. The 
role of adenosine as a neurotransmitter and 
neuromodulator in the CNS has been experimentally 
confirmed: its increased accumulation is associated 
with the occurrence of headaches, nausea and 
somnolence. Adenosine has an inhibitory effect in 
the CNS: when binding to adenosine A1 receptors in 
the perifornical area of hypothalamus, adenosine 
can regulate the awakening and falling asleep 
processes, which may explain the weakness and 
somnolence that some patients experience after 
taking methotrexate.25 In children treated with high 
doses of methotrexate, its neurotoxic effect was 
manifested in the pronounced somnolence and 
comatose state, which were reversible with 
theophylline therapy, a nonselective adenosine 
receptor antagonist. The neurotoxic effect of 
methotrexate may also be due to excitotoxic death of 
neurons, which can be caused by homocysteine 
metabolites: homocysteine acid and cysteine 
sulfonic acids.26 Another possible mechanism may 
be impaired metabolism of biopterin, leading to a 
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Rarely, low doses of methotrexate cause 
osteopathies like bone pain, long bone fractures, and 
osteoporosis. 
 
Methotrexate-induced osteopathy syndrome was 
first described as a stress fracture of the lower 
extremity bones, diffuse bone pain, and osteoporosis 
in children with acute lymphoblastic leukemia 
receiving long-term therapy with low-dose 
methotrexate. Several cases of methotrexate-
induced osteopathy in patients with rheumatoid 
arthritis and psoriasis have been described. An 
animal study has found that long-term use of low-
dose methotrexate causes pronounced osteopenia by 
reducing osteoblast activity and increasing 
osteoclast activity.28  
 
It should be considered that in some cases, even a 
single dose of methotrexate may lead to serious and 
complex ADR. The risk of fatal ADR with 
methotrexate therapy is small. The toxic effects of 
methotrexate on the hematopoietic system, 
respiratory system and liver are most life 
threatening. Therefore, careful identification of risk 
factors for increased toxicity of methotrexate and 
comprehensive monitoring of the patient’s 
condition with regard to these ADR groups is 
necessary. Hepatologic and hematologic ADR of 
methotrexate may manifest as weakness, nausea, 
stomatitis, and syncope in patients. Similar 
symptoms that develop during methotrexate 
therapy should be alerted. Careful monitoring of the 
patient’s condition will reduce the risk of ADR. 
Caution should be exercised in patients with 
hepatitis, hepatic cirrhosis, and other conditions 
associated with impaired hepatic function due to its 
potential hepatotoxicity. Liver parameters should be 
closely monitored in these patients. 
  
Despite the lack of unambiguous data regarding the 
complete or partial prohibition on alcohol 
consumption in the period of methotrexate therapy, 
history of alcoholism and alcohol-induced liver 
diseases are relative contraindications to the drug 
administration. The use of methotrexate may be 
restricted by administration of other drugs that have 
toxic effects on the liver. Since the drug is primarily 
excreted by the kidneys, methotrexate should be 
used with caution in patients with renal impairment. 
With impaired renal excretion of methotrexate, 
plasma concentrations of the drug increase and 
therefore the risk of its toxicity increases. Close 
attention should be paid to the state of patients with 
immunosuppression and chronic infections prone to 
exacerbation as a result of immunosuppressive effect 
of methotrexate. In exacerbation of the infectious 
process, the drug should be temporarily 
discontinued. Before prescribing methotrexate, it is 
necessary to assess whether the patient is able to 
fulfil all prescriptions responsibly, since the therapy 
success and patient’s safety depend largely on careful 
selection of the dose regimen and duration of 
therapy, as well as on regular examination for 
potential ADR.  
 
Often, a potential benefit of therapy may outweigh 
the possible risks for a patient with a disease or 
condition that limits the use of methotrexate. 
Treatment decisions should be made by the 
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